DK1525320T3 - Fremgangsmåde til ekspression af rekombinant protein i CHO-celler - Google Patents

Fremgangsmåde til ekspression af rekombinant protein i CHO-celler

Info

Publication number
DK1525320T3
DK1525320T3 DK03765075T DK03765075T DK1525320T3 DK 1525320 T3 DK1525320 T3 DK 1525320T3 DK 03765075 T DK03765075 T DK 03765075T DK 03765075 T DK03765075 T DK 03765075T DK 1525320 T3 DK1525320 T3 DK 1525320T3
Authority
DK
Denmark
Prior art keywords
cho cells
expression
recombinant protein
enhancing
expression vector
Prior art date
Application number
DK03765075T
Other languages
Danish (da)
English (en)
Inventor
Robert Kallmeier
Robert Peptech Gay
Original Assignee
Lonza Biologics Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9940670&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1525320(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lonza Biologics Plc filed Critical Lonza Biologics Plc
Application granted granted Critical
Publication of DK1525320T3 publication Critical patent/DK1525320T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
    • C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/108—Plasmid DNA episomal vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/42—Vector systems having a special element relevant for transcription being an intron or intervening sequence for splicing and/or stability of RNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DK03765075T 2002-07-18 2003-07-21 Fremgangsmåde til ekspression af rekombinant protein i CHO-celler DK1525320T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0216648.6A GB0216648D0 (en) 2002-07-18 2002-07-18 Method of expressing recombinant protein in CHO cells
PCT/EP2003/007946 WO2004009823A1 (fr) 2002-07-18 2003-07-21 Technique d'expression de proteines de recombinaison dans des cellules d'ovaire de hamster chinois (cho)

Publications (1)

Publication Number Publication Date
DK1525320T3 true DK1525320T3 (da) 2009-02-23

Family

ID=9940670

Family Applications (1)

Application Number Title Priority Date Filing Date
DK03765075T DK1525320T3 (da) 2002-07-18 2003-07-21 Fremgangsmåde til ekspression af rekombinant protein i CHO-celler

Country Status (14)

Country Link
US (3) US20060003405A1 (fr)
EP (1) EP1525320B1 (fr)
CN (1) CN1296486C (fr)
AT (1) ATE412761T1 (fr)
AU (2) AU2003251434B2 (fr)
CA (2) CA2489016C (fr)
DE (1) DE60324430D1 (fr)
DK (1) DK1525320T3 (fr)
ES (1) ES2314248T3 (fr)
GB (1) GB0216648D0 (fr)
HK (1) HK1081595A1 (fr)
PT (1) PT1525320E (fr)
SI (1) SI1525320T1 (fr)
WO (1) WO2004009823A1 (fr)

Families Citing this family (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0216648D0 (en) * 2002-07-18 2002-08-28 Lonza Biologics Plc Method of expressing recombinant protein in CHO cells
GB0319451D0 (en) * 2003-08-19 2003-09-17 Lonza Biologics Plc Tropolone assay
JP4809828B2 (ja) 2004-03-30 2011-11-09 グラクソ グループ リミテッド 免疫グロブリン
TWI307630B (en) 2004-07-01 2009-03-21 Glaxo Group Ltd Immunoglobulins
JP2008536506A (ja) * 2005-04-22 2008-09-11 ロンザ・バイオロジクス・ピーエルシー ｍＣＭＶプロモーターおよびｈＣＭＶ主要最初期遺伝子を含む哺乳類発現ベクター
EP1915394B1 (fr) * 2005-05-20 2021-01-27 Lonza Biologics plc. Expression de niveau eleve d'un anticorps recombinant d'une cellule hote de mammifere
JP4997239B2 (ja) 2005-07-22 2012-08-08 ワイズ・エー・シー株式会社 抗ｃｄ２６抗体およびその使用方法
US9884899B2 (en) 2007-07-06 2018-02-06 Promedior, Inc. Methods for treating fibrosis using CRP antagonists
US20090053786A1 (en) 2007-07-09 2009-02-26 Yung-Hsiang Kao Prevention of disulfide bond reduction during recombinant production of polypeptides
UY32341A (es) 2008-12-19 2010-07-30 Glaxo Group Ltd Proteínas de unión antígeno novedosas
CA2754961C (fr) 2009-03-11 2018-04-10 Promedior, Inc. Procedes de traitement et de diagnostic pour troubles d'hypersensibilite
JP5980508B2 (ja) 2009-03-11 2016-08-31 プロメディオール， インコーポレイテッド 自己免疫障害に対する処置方法
UA110323C2 (en) 2009-06-04 2015-12-25 Promedior Inc Derivative of serum amyloid p and their receipt and application
JP5822826B2 (ja) 2009-06-17 2015-11-24 プロメディオール， インコーポレイテッド Ｓａｐ変異体及びその使用
LT2464725T (lt) * 2009-08-11 2020-06-10 F. Hoffmann-La Roche Ag Baltymų gamyba ląstelių mitybinėje terpėje, kurioje nėra glutamino
WO2011080050A2 (fr) 2009-12-11 2011-07-07 Novartis Ag Molécules de liaison
AU2011209713B2 (en) 2010-01-28 2014-04-03 Glaxo Group Limited CD127 binding proteins
UA123257C2 (uk) 2010-02-24 2021-03-10 Іммуноджен, Інк. Виділений поліпептид, що кодує антитіло до рецептора фолієвої кислоти 1
UA108227C2 (xx) 2010-03-03 2015-04-10 Антигензв'язуючий білок
EP3620467A1 (fr) 2010-03-12 2020-03-11 Debiopharm International SA Molécules de liaison cd37 et immunoconjugués correspondants
UY33421A (es) 2010-06-03 2011-12-30 Glaxo Wellcome House Proteinas de union al antígeno humanizados
WO2012010635A1 (fr) 2010-07-22 2012-01-26 Glaxosmithkline Biologicals S.A. Nouvelles protéines de liaison à un antigène
WO2012019024A2 (fr) 2010-08-04 2012-02-09 Immunogen, Inc. Molécules se liant à her3 et leurs immunoconjugués
EP3357511B1 (fr) 2011-06-30 2020-05-13 Genzyme Corporation Inhibiteurs d'activation de lymphocytes t
CA2841745A1 (fr) 2011-07-15 2013-01-24 Oncomed Pharmaceuticals, Inc. Agents de fixation aux proteines rspo et leurs utilisations
US9549981B2 (en) 2011-07-19 2017-01-24 Philogen S.P.A. Sequential antibody therapy
UY34317A (es) 2011-09-12 2013-02-28 Genzyme Corp Anticuerpo antireceptor de célula T (alfa)/ß
KR102091293B1 (ko) 2011-09-23 2020-03-20 온코메드 파마슈티칼스, 인크. Vegf/dll4 결합제 및 그의 용도
CN108424456B (zh) 2011-11-23 2022-04-26 医学免疫有限责任公司 特异于her3的结合分子及其用途
JP2015520192A (ja) 2012-06-06 2015-07-16 オンコメッド ファーマシューティカルズ インコーポレイテッド Ｈｉｐｐｏ経路を調節する結合剤およびその使用
EP2674495A1 (fr) * 2012-06-14 2013-12-18 Sanofi Système d'expression dans CHO
KR20150036603A (ko) 2012-07-13 2015-04-07 온코메드 파마슈티칼스, 인크. Rspo3 결합제 및 그의 용도
NZ726258A (en) 2012-08-31 2019-07-26 Immunogen Inc Antibodies and uses thereof to detect folate receptor 1
ES2540753T3 (es) 2012-09-24 2015-07-13 Lonza Biologics Plc. Vectores de expresión que comprenden secuencias quiméricas de promotor y amplificador de citomegalovirus
KR20150090919A (ko) 2012-12-04 2015-08-06 온코메드 파마슈티칼스, 인크. 결합제를 사용한 면역요법
WO2014100073A2 (fr) * 2012-12-21 2014-06-26 Merck Sharp & Dohme Corp. Vecteurs d'expression utilisables en vue de la production de protéines recombinées dans des cellules de mammifère
SG10201907501QA (en) 2013-08-30 2019-10-30 Immunogen Inc Antibodies and assays for detection of folate receptor 1
EP3069137A1 (fr) 2013-11-05 2016-09-21 Novartis Ag Composés organiques
CN105829547A (zh) 2013-12-02 2016-08-03 昂科梅德制药有限公司 与Wnt途径抑制剂有关的预测性生物标记物的鉴别
KR102489452B1 (ko) 2014-02-02 2023-01-16 메디뮨 리미티드 Ngf 길항제 도메인 및 tnfa 길항제 도메인으로 구성된 키메라 단백질
US8961992B1 (en) * 2014-04-02 2015-02-24 Tunitas Therapeutics, Inc. Epsigam fusion protein
PL3128997T3 (pl) 2014-04-08 2020-12-28 Boston Pharmaceuticals Inc. Cząsteczki wiążące specyficznie il-21 i ich zastosowania
KR20160143808A (ko) 2014-04-11 2016-12-14 메디뮨 엘엘씨 이중특이적 her2 항체
WO2015165480A1 (fr) 2014-04-30 2015-11-05 Institute For Research In Biomedicine Compositions de vaccin de cytomégalovirus humain et leur procédé de production
BR112016027845A2 (pt) 2014-05-29 2017-10-31 Medimmune Llc proteínas de fusão de ox40l e usos das mesmas
SG10201913406SA (en) * 2014-07-18 2020-03-30 Celltheon Corp Methods and compositions for expression of polypeptides in a cell
CN104195173B (zh) * 2014-09-02 2017-03-08 北京比洋生物技术有限公司 具有双表达盒的谷氨酰胺合成酶高效表达载体
TW201619200A (zh) 2014-10-10 2016-06-01 麥迪紐有限責任公司 人類化抗－ｏｘ４０抗體及其用途
WO2016059602A2 (fr) 2014-10-16 2016-04-21 Glaxo Group Limited Méthodes de traitement du cancer et compositions associées
CN107001472B (zh) 2014-11-10 2020-12-11 免疫医疗有限公司 对cd73具有特异性的结合分子及其用途
GB2538120A (en) 2014-11-11 2016-11-09 Medimmune Ltd Therapeutic combinations comprising anti-CD73 antibodies and uses thereof
CN104561091A (zh) * 2014-12-17 2015-04-29 华南理工大学 一种光学分析检测cho细胞增殖的方法及应用
CN105779501A (zh) * 2014-12-26 2016-07-20 上海药明康德新药开发有限公司 运用cho宿主细胞进行重组蛋白的瞬时表达生产的方法
CN105802995A (zh) * 2014-12-31 2016-07-27 上海复宏汉霖生物技术有限公司 一种利用cho细胞生产重组蛋白的基因表达系统及真核表达载体
US10351630B2 (en) 2015-01-09 2019-07-16 Medimmune, Llc Assay to detect human DPP-4
CA2985029A1 (fr) 2015-05-04 2016-11-10 Vcn Biosciences Sl Adenovirus oncolytiques comprenant des mutations dans les epitopes d'adenovirus immunodominants et leur utilisation dans le traitement d'un cancer
RU2739612C2 (ru) 2015-06-29 2020-12-28 Иммуноджен, Инк. Анти-cd123 антитела и их конъюгаты и производные
KR20180033588A (ko) 2015-08-12 2018-04-03 메디뮨 리미티드 Ｇｉｔｒｌ 융합 단백질 및 그의 용도
US11339213B2 (en) 2015-09-23 2022-05-24 Mereo Biopharma 5, Inc. Methods and compositions for treatment of cancer
CA3001364A1 (fr) 2015-10-09 2017-04-13 Genzyme Corporation Technologie flare (flow cytometry attenuated reporter expression, expression de reporter attenuee par cytometrie en flux) pour tri en vrac rapide
AU2016352967A1 (en) 2015-11-10 2018-06-21 Medimmune, Llc Binding molecules specific for ASCT2 and uses thereof
KR20230152153A (ko) 2016-03-10 2023-11-02 악셀레론 파마 인코포레이티드 액티빈 타입 2 수용체 결합 단백질 및 이의 용도
EP3426686A4 (fr) 2016-04-15 2019-11-06 Alder Biopharmaceuticals, Inc. Anticorps anti-pacap humanisés et leurs utilisations
US20180126000A1 (en) 2016-06-02 2018-05-10 Abbvie Inc. Glucocorticoid receptor agonist and immunoconjugates thereof
SG11201903018WA (en) 2016-10-07 2019-05-30 Genzyme Corp Early post-transfection isolation of cells (epic) for biologics production
WO2018071345A1 (fr) 2016-10-11 2018-04-19 Integrated Biotherapeutics, Inc. Anticorps neutralisant à large spectre ciblant la boucle de fusion interne de la glycoprotéine du virus ebola
CA3044574A1 (fr) 2016-11-23 2018-05-31 Bioverativ Therapeutics Inc. Anticorps bispecifiques se liant au facteur ix de coagulation et au facteur x de coagulation
CN107973841B (zh) * 2016-12-23 2022-03-25 浙江海隆生物科技有限公司 Cho细胞表达的重组牛病毒性腹泻病毒e2蛋白及亚单位疫苗的制备方法和应用
JP7467119B2 (ja) 2017-02-17 2024-04-15 ロンザ リミテッド 発現困難タンパク質のための多部位ｓｓｉ細胞
GB201703418D0 (en) 2017-03-03 2017-04-19 Ge Healthcare Bio Sciences Ab Method for cell line development
CN110785494B (zh) 2017-06-16 2024-07-02 隆萨有限公司 用于生产生物制品的通用自调节哺乳动物细胞系平台
KR20200095477A (ko) 2017-12-01 2020-08-10 애브비 인코포레이티드 글루코코르티코이드 수용체 작용제 및 이의 면역접합체
EP3902824A4 (fr) 2018-12-28 2023-01-04 Sparx Therapeutics Inc. Molécules de liaison spécifiques de la claudine 18.2, compositions et procédés associés, pour le traitement du cancer et d'autres maladies
AU2020253455A1 (en) 2019-04-03 2021-11-04 Genzyme Corporation Anti-alpha beta TCR binding polypeptides with reduced fragmentation
CA3144252A1 (fr) 2019-06-18 2020-12-24 United Therapeutics Corporation Traitement mitochondrial d'organes pour une transplantation
CN113005140B (zh) * 2019-12-19 2024-03-15 鲁南制药集团股份有限公司 一种具有双表达盒的gs表达载体及其应用
WO2021251340A1 (fr) 2020-06-08 2021-12-16 ワイズ・エー・シー株式会社 Agent pour inverser la résistance à des médicaments anticancéreux
CN117279942A (zh) 2020-09-28 2023-12-22 免疫医疗有限公司 用于治疗疼痛的化合物和方法
JP2022184105A (ja) 2021-05-31 2022-12-13 ワイズ・エー・シー株式会社 抗ｃｄ２６抗体と免疫チェックポイント阻害剤との併用療法
US11807685B2 (en) 2021-08-05 2023-11-07 The Uab Research Foundation Anti-CD47 antibody and uses thereof
CA3234162A1 (fr) 2021-10-15 2023-04-20 Michele Fiscella Anticorps et leurs procedes d'utilisation
WO2024062074A1 (fr) 2022-09-21 2024-03-28 Sanofi Biotechnology Anticorps anti-il-1r3 humanisé et procédés d'utilisation

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2944850A1 (de) * 1979-11-07 1981-05-27 Bayer Ag, 5090 Leverkusen Mittel zur regulierung des pflanzenwachstums, deren herstellung und deren verwendung
US4968615A (en) * 1985-12-18 1990-11-06 Ciba-Geigy Corporation Deoxyribonucleic acid segment from a virus
US4963481A (en) * 1985-12-18 1990-10-16 Genetics Institute Inc Promoter system
GB8601597D0 (en) * 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US5891693A (en) * 1990-01-25 1999-04-06 Alusuisse Holdings A.G. Recombinant DNA methods vectors and host cells
IT1262545B (it) 1993-10-25 1996-07-02 Menarini Ricerche Sud S P A A Sistema di espressione per linee cellulari eucariotiche
DK0731845T3 (da) * 1993-12-23 2003-10-20 Merck & Co Inc Homologt rekombinant antistofekspressionssystem til murine celler
AU684134B2 (en) * 1994-02-07 1997-12-04 Qiagen Gmbh Nucleic acid transfection efficiency increase by use of isopropanol in aqueous solutions
GB0216648D0 (en) * 2002-07-18 2002-08-28 Lonza Biologics Plc Method of expressing recombinant protein in CHO cells
JP5171033B2 (ja) 2003-03-11 2013-03-27 メルク セローノ ソシエテ アノニム ｍＣＭＶＩＥ２プロモーターを含んで成る発現ベクター

Also Published As

Publication number Publication date
DE60324430D1 (de) 2008-12-11
CA2489016C (fr) 2012-01-17
AU2003251434A1 (en) 2004-02-09
CA2672809C (fr) 2013-01-08
EP1525320A1 (fr) 2005-04-27
GB0216648D0 (en) 2002-08-28
CN1296486C (zh) 2007-01-24
SI1525320T1 (sl) 2009-02-28
HK1081595A1 (en) 2006-05-19
CA2672809A1 (fr) 2004-01-29
CN1668749A (zh) 2005-09-14
US20060003405A1 (en) 2006-01-05
US20110104745A1 (en) 2011-05-05
EP1525320B1 (fr) 2008-10-29
AU2003251434B2 (en) 2009-03-05
CA2489016A1 (fr) 2004-01-29
PT1525320E (pt) 2009-01-23
US20080138902A1 (en) 2008-06-12
ATE412761T1 (de) 2008-11-15
AU2009200665B2 (en) 2012-08-16
WO2004009823A1 (fr) 2004-01-29
ES2314248T3 (es) 2009-03-16
US7932087B2 (en) 2011-04-26
AU2009200665A1 (en) 2009-03-12

Similar Documents

Publication Publication Date Title
DK1525320T3 (da) Fremgangsmåde til ekspression af rekombinant protein i CHO-celler
ATE437652T1 (de) Verwendung von hmgb1 zur aktivierung dendritischer zellen
DK1532261T3 (da) Fremgangsmåder og DNA-konstrukter til produktion af polypeptider med højt udbytte
ATE514433T1 (de) Nucleotid und zelluläre vakzine-zusammensetzung
DK1948789T3 (da) Fremgangsmåde til fremstilling af permanente, humane cellelinjer
DK2287288T3 (da) Medium frit for animalsk protein til dyrkning af celler
DK1553975T3 (da) Optimerede Fc-varianter og fremgangsmåder til generering heraf.
CY1118782T1 (el) Επιλογη κυτταρων που εκφραζουν ετερομερη πολυπεπτιδια
DE60144145D1 (de) Subtilisin-variante
DK1918364T3 (da) Fremgangsmåde til rekloning af produktionsceller
DK1210411T3 (da) Sammensætninger og fremgangsmåder til forbedret celledyrkning
NZ521396A (en) Fusion proteins comprising two or more Neisseria polypeptides
DK1379671T3 (da) Fremgangsmåder til dyrkning af circovirus
DK1697523T3 (da) Ekspressionsvektor til antibiotikafri ekspression
ATE460176T1 (de) Mikrosomvakzin
ATE474926T1 (de) Verwendung von clya hemolysin fur ausscheidung von fusionprotein
ATE514784T1 (de) Zellpräparation
GB0208041D0 (en) Method of culturing animal cells
DK1025245T3 (da) Hurtig etablering af stabile pattedyrscelelinjer, der producerer höje koncentrationer af rekombinante proteiner
ATE466874T1 (de) Mit scytovirin der domäne 1 verwandte polypeptide
DK1756273T3 (da) Signalpeptid til frembringelse af et polypeptid
NO20083609L (no) Fremgangsmater og sammensetninger for malrettet-RELT
DK1572133T3 (da) Fremgangsmåde til identificering af modulatorer af den humane orexin-2-receptor
SG146623A1 (en) Rodent expression systems utilising polyoma virus and epstein barr virus sequences
ATE299932T1 (de) Verfahren der zellkultivierung